Pablo Nenclares

11PUBLICATIONS
51CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGenomicsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 19, 2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.

|Aug 01, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed

|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|Aug 12, 2024
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Emmanuel C Patin, Pablo Nenclares, Charleen Chan Wah Hak

|Jul 26, 2024
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Edward Armstrong, Matthew K L Chiu, Shane Foo

|Mar 13, 2024
FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA.

Ann-Marie Baker, Gayathri Nageswaran, Pablo Nenclares

Pageof 2

Frequent Collaborators

9 joint publications

Kevin J Harrington

6 joint publications

Emmanuel Patin

6 joint publications

Alan Melcher

3 joint publications

Shane Foo